Evidence map›Paper›PMID 35489014›Full record

ArticleAdvances in therapy2022

Improving Care in Eosinophil-Associated Diseases: A Charter.

David J Jackson, Praveen Akuthota, Rebeca Andradas, Albert J Bredenoord, Amanda Cordell, Sarah Gray, Joyce Kullman, Sameer K Mathur, Ian Pavord, Florence Roufosse and 5 more

Abstract read
In one paragraph

Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Eosinophilic-Associated Disease Overlap: What Do We Know About It?Allergy, asthma & immunology research · 2023
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

David J JacksonGuy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, School of Immunology and Microbial Sciences, King's College London, London, SE1 9RT, UK. David.Jackson@gstt.nhs.uk.
Praveen AkuthotaDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA.
Rebeca AndradasSpanish Association of Eosinophilic Esophagitis-AEDESEO, Madrid, Spain.
Albert J BredenoordDepartment of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Amanda CordellEOS Network Eosinophilic Diseases Charity, Colchester, England, UK.
Sarah GrayAusEE Inc., Queensland, Australia.
Joyce KullmanVasculitis Foundation, Kansas City, MO, USA.
Sameer K MathurDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Ian PavordOxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Florence RoufosseDepartment of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Christian RubioGlobal Genes, Boston, MA, USA.
Irena Clisson RusekAssociation Pour l'Information sur les Maladies à Eosinophiles-APIMEO, Bourg-la-Reine, France.
Dagmar SimonDepartment of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Mary Jo StrobelAmerican Partnership for Eosinophilic Disorders, Atlanta, GA, USA.
Tonya WindersAllergy and Asthma Network, Vienna, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.

Indexed as

AsthmaEosinophiliaEosinophilsHumansQuality ImprovementQuality of LifeEosinophil-associated diseasesEosinophilic immune dysfunction (EID)Healthcare professional (HCP) educationMultidisciplinary teams (MDTs)Patient educationPatient rightsTimely diagnosis

Identifiers

PMID35489014
PMCPMC9055373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.